Drugs / FBR-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05279352 | Mar → Jun 2022 | COVID-19 | Fab'entech | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FBR-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05279352 ↗ |
| Action | Inhibit | “Fab'entech proposes a way to block this event, neutralizing viral replication, and therefore inhibiting pathogenic activity of the virus.” NCT05279352 ↗ |
| Modality | Protein / enzyme biologic | “Fab'entech is currently developing polyclonal F(ab')2 equine fragments directed against the SARS-CoV-2 spike protein.” NCT05279352 ↗ |